AR102594A1 - ANTICUERPOS ANTI-IL-1b Y MÉTODOS DE USO - Google Patents
ANTICUERPOS ANTI-IL-1b Y MÉTODOS DE USOInfo
- Publication number
- AR102594A1 AR102594A1 ARP150103647A ARP150103647A AR102594A1 AR 102594 A1 AR102594 A1 AR 102594A1 AR P150103647 A ARP150103647 A AR P150103647A AR P150103647 A ARP150103647 A AR P150103647A AR 102594 A1 AR102594 A1 AR 102594A1
- Authority
- AR
- Argentina
- Prior art keywords
- amino acid
- hvr
- seq
- acid sequence
- acid residue
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
- C07K16/245—IL-1
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2299/00—Coordinates from 3D structures of peptides, e.g. proteins or enzymes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Ophthalmology & Optometry (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14192523 | 2014-11-10 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR102594A1 true AR102594A1 (es) | 2017-03-08 |
Family
ID=51868114
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP150103647A AR102594A1 (es) | 2014-11-10 | 2015-11-09 | ANTICUERPOS ANTI-IL-1b Y MÉTODOS DE USO |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US10344085B2 (enExample) |
| EP (1) | EP3218402A1 (enExample) |
| JP (1) | JP6787888B2 (enExample) |
| KR (1) | KR20170081253A (enExample) |
| CN (1) | CN107074942A (enExample) |
| AR (1) | AR102594A1 (enExample) |
| AU (1) | AU2015345320A1 (enExample) |
| BR (1) | BR112017009817A2 (enExample) |
| CA (1) | CA2963719A1 (enExample) |
| IL (1) | IL251165A0 (enExample) |
| MX (1) | MX2017005987A (enExample) |
| RU (1) | RU2017120358A (enExample) |
| SG (1) | SG11201702550WA (enExample) |
| TW (1) | TW201632552A (enExample) |
| WO (1) | WO2016075034A1 (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT2417156E (pt) | 2009-04-07 | 2015-04-29 | Roche Glycart Ag | Anticorpos trivalentes, biespecíficos |
| SG11201702550WA (en) | 2014-11-10 | 2017-04-27 | Hoffmann La Roche | ANTI-IL-1beta ANTIBODIES AND METHODS OF USE |
| EP3218400A1 (en) | 2014-11-10 | 2017-09-20 | F. Hoffmann-La Roche AG | Anti-pdgf-b antibodies and methods of use |
| JP2017537896A (ja) | 2014-11-10 | 2017-12-21 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | 二重特異性抗体及び眼科に使用する方法 |
| WO2016075035A1 (en) | 2014-11-10 | 2016-05-19 | F. Hoffmann-La Roche Ag | Anti-ang2 antibodies and methods of use |
| WO2016087416A1 (en) | 2014-12-03 | 2016-06-09 | F. Hoffmann-La Roche Ag | Multispecific antibodies |
| WO2018212556A1 (en) * | 2017-05-16 | 2018-11-22 | Cj Healthcare Corporation | A method for purifying an antibody or an antibody fragment thereof using affinity chromatography |
| KR102087823B1 (ko) * | 2017-05-16 | 2020-03-13 | 에이치케이이노엔 주식회사 | 친화성 크로마토그래피를 이용한 항체 또는 항체절편 정제 방법 |
| WO2018231827A1 (en) | 2017-06-12 | 2018-12-20 | Bluefin Biomedicine, Inc. | Anti-il1rap antibodies and antibody drug conjugates |
| BR112020015006A2 (pt) * | 2018-01-26 | 2020-12-29 | Genzyme Corporation | Variantes de fc com ligação realçada ao fcrn e meia-vida prolongada |
| CN110818793A (zh) * | 2018-08-14 | 2020-02-21 | 中山康方生物医药有限公司 | 抗IL-1β的抗体、其药物组合物及其用途 |
| WO2020127873A1 (en) * | 2018-12-21 | 2020-06-25 | F. Hoffmann-La Roche Ag | Antibody that binds to vegf and il-1beta and methods of use |
| CN117343173A (zh) * | 2019-03-07 | 2024-01-05 | 瑞阳(苏州)生物科技有限公司 | 人IL-1β蛋白结合分子及其编码基因和应用 |
| CN114026127B (zh) | 2019-06-11 | 2024-10-29 | 生物蛋白有限公司 | 条件活性抗epcam抗体、抗体片段、其免疫缀合物以及其用途 |
| CN114466663B (zh) | 2019-07-25 | 2026-01-02 | 建新公司 | 以FcRn拮抗剂治疗抗体介导的障碍的方法 |
| CN114524875B (zh) * | 2021-11-11 | 2023-07-25 | 江苏莱森生物科技研究院有限公司 | 偶联IL-1β单克隆抗体的纳米硅球及应用 |
| CN117126278B (zh) * | 2023-10-26 | 2024-01-05 | 中国科学院苏州纳米技术与纳米仿生研究所 | 一种单克隆抗体及其应用 |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4935343A (en) * | 1986-08-08 | 1990-06-19 | Syntex (U.S.A.) Inc. | Monoclonal antibodies for interleukin-1β |
| AU2003208946A1 (en) * | 2002-02-28 | 2003-09-16 | Eli Lilly And Company | Anti-interleukin-1 beta analogs |
| CN1678634A (zh) | 2002-06-28 | 2005-10-05 | 多曼蒂斯有限公司 | 免疫球蛋白单个变体抗原结合区及其特异性构建体 |
| JP4538461B2 (ja) * | 2003-01-24 | 2010-09-08 | アプライド モレキュラー エボリューション，インコーポレイテッド | ヒトＩＬ−１βアンタゴニスト |
| WO2005052002A2 (en) * | 2003-11-20 | 2005-06-09 | Massachusetts Institute Of Technology | Single-domain antibodies and uses thereof |
| US20050282233A1 (en) | 2004-03-05 | 2005-12-22 | Ludwig Institute For Cancer Research | Multivalent antibody materials and methods for VEGF/PDGF family of growth factors |
| US7612181B2 (en) | 2005-08-19 | 2009-11-03 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
| US8268314B2 (en) | 2008-10-08 | 2012-09-18 | Hoffmann-La Roche Inc. | Bispecific anti-VEGF/anti-ANG-2 antibodies |
| NZ593905A (en) * | 2009-01-29 | 2013-03-28 | Abbott Lab | Il-1 binding proteins |
| AU2010306681A1 (en) * | 2009-10-15 | 2012-04-19 | Abbvie Inc. | IL-1 binding proteins |
| TWI426920B (zh) | 2010-03-26 | 2014-02-21 | Hoffmann La Roche | 雙專一性、雙價抗－ｖｅｇｆ／抗－ａｎｇ－２抗體 |
| CN104474546A (zh) * | 2010-08-13 | 2015-04-01 | 弗·哈夫曼-拉罗切有限公司 | 用于疾病治疗的针对IL-1β和IL-18的抗体 |
| WO2012034039A2 (en) * | 2010-09-10 | 2012-03-15 | Apexigen, Inc. | Anti-il-1 beta antibodies and methods of use |
| MX2013007332A (es) * | 2010-12-21 | 2014-01-23 | Abbvie Inc | Inmunoglobulinas de dominio variable doble biespecificas de il-1 alfa y beta y su uso. |
| EP2726088B1 (en) | 2011-06-29 | 2019-01-02 | Amgen Inc. | Predictive biomarker of survival in the treatment of renal cell carcinoma |
| SG11201408196RA (en) | 2012-06-28 | 2015-03-30 | Molecular Partners Ag | Designed ankyrin repeat proteins binding to platelet-derived growth factor |
| SI3495387T1 (sl) | 2012-07-13 | 2021-12-31 | Roche Glycart Ag | Bispecifična protitelesa proti VEGF/proti ANG-2 in njihova uporaba pri zdravljenju bolezni očesnih žil |
| US20140093498A1 (en) | 2012-09-28 | 2014-04-03 | Boehringer Ingelheim International Gmbh | Pharmaceutical combinations comprising dual angiopoietin-2 / dll4 binders and anti-vegf-r agents |
| WO2014049100A1 (en) | 2012-09-28 | 2014-04-03 | Boehringer Ingelheim International Gmbh | Pharmaceutical combinations comprising dual angiopoietin-2 / dll4 binders and anti-vegf agents |
| AU2013342275B2 (en) | 2012-11-08 | 2017-11-09 | Clearside Biomedical, Inc. | Methods and devices for the treatment of ocular diseases in human subjects |
| RU2015115956A (ru) | 2012-11-09 | 2017-01-10 | Пфайзер Инк. | Антитела, специфичные в отношении фактора роста тромбоцитов в, и их композиции и применения |
| JO3405B1 (ar) | 2013-01-09 | 2019-10-20 | Regeneron Pharma | الأجسام المضادة لمضاد مستقبل عامل النمو المشتق من الصفائح الدموية - بيتا واستخداماتها |
| AU2014227732A1 (en) * | 2013-03-15 | 2015-09-17 | Abbvie Inc. | Dual specific binding proteins directed against IL-1 beta and IL-17 |
| CA2904806C (en) * | 2013-04-29 | 2021-11-23 | F. Hoffmann-La Roche Ag | Human fcrn-binding modified antibodies and methods of use |
| CN105611944A (zh) | 2013-12-20 | 2016-05-25 | 豪夫迈·罗氏有限公司 | 抗ang2抗体和cd40激动剂的组合疗法 |
| CN110903398B (zh) | 2014-01-15 | 2023-08-15 | 豪夫迈·罗氏有限公司 | 具有修饰的FCRN和保持的蛋白A结合性质的Fc区变体 |
| EP3218400A1 (en) | 2014-11-10 | 2017-09-20 | F. Hoffmann-La Roche AG | Anti-pdgf-b antibodies and methods of use |
| WO2016075035A1 (en) | 2014-11-10 | 2016-05-19 | F. Hoffmann-La Roche Ag | Anti-ang2 antibodies and methods of use |
| JP2017537896A (ja) | 2014-11-10 | 2017-12-21 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | 二重特異性抗体及び眼科に使用する方法 |
| SG11201702550WA (en) | 2014-11-10 | 2017-04-27 | Hoffmann La Roche | ANTI-IL-1beta ANTIBODIES AND METHODS OF USE |
| WO2016209972A1 (en) | 2015-06-26 | 2016-12-29 | Amgen Inc. | Biomarker of survival in the treatment of renal cell carcinoma with a vegfr inhibitor and an ang2 inhibitor |
| BR112019022074A2 (pt) | 2017-06-02 | 2020-05-12 | Boehringer Ingelheim International Gmbh | Terapia de combinação anticâncer |
-
2015
- 2015-11-06 SG SG11201702550WA patent/SG11201702550WA/en unknown
- 2015-11-06 AU AU2015345320A patent/AU2015345320A1/en not_active Abandoned
- 2015-11-06 CN CN201580060880.4A patent/CN107074942A/zh active Pending
- 2015-11-06 MX MX2017005987A patent/MX2017005987A/es unknown
- 2015-11-06 WO PCT/EP2015/075875 patent/WO2016075034A1/en not_active Ceased
- 2015-11-06 CA CA2963719A patent/CA2963719A1/en not_active Abandoned
- 2015-11-06 EP EP15790945.8A patent/EP3218402A1/en not_active Withdrawn
- 2015-11-06 BR BR112017009817A patent/BR112017009817A2/pt not_active Application Discontinuation
- 2015-11-06 KR KR1020177015590A patent/KR20170081253A/ko not_active Withdrawn
- 2015-11-06 JP JP2017525023A patent/JP6787888B2/ja not_active Expired - Fee Related
- 2015-11-06 RU RU2017120358A patent/RU2017120358A/ru not_active Application Discontinuation
- 2015-11-09 AR ARP150103647A patent/AR102594A1/es unknown
- 2015-11-09 TW TW104136907A patent/TW201632552A/zh unknown
-
2017
- 2017-03-14 IL IL251165A patent/IL251165A0/en unknown
- 2017-05-09 US US15/590,161 patent/US10344085B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CA2963719A1 (en) | 2016-05-19 |
| JP6787888B2 (ja) | 2020-11-18 |
| US20170247447A1 (en) | 2017-08-31 |
| SG11201702550WA (en) | 2017-04-27 |
| WO2016075034A1 (en) | 2016-05-19 |
| IL251165A0 (en) | 2017-04-30 |
| AU2015345320A1 (en) | 2017-04-06 |
| MX2017005987A (es) | 2017-06-29 |
| RU2017120358A3 (enExample) | 2019-05-29 |
| CN107074942A (zh) | 2017-08-18 |
| TW201632552A (zh) | 2016-09-16 |
| JP2017534646A (ja) | 2017-11-24 |
| BR112017009817A2 (pt) | 2018-02-14 |
| KR20170081253A (ko) | 2017-07-11 |
| RU2017120358A (ru) | 2018-12-13 |
| US10344085B2 (en) | 2019-07-09 |
| EP3218402A1 (en) | 2017-09-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR102592A1 (es) | Anticuerpos biespecíficos y métodos de uso en oftalmología | |
| AR102593A1 (es) | Anticuerpos anti-pdgf-b y métodos de uso | |
| PE20161571A1 (es) | Anticuerpos anti-ox40 y metodos de uso | |
| RU2017120358A (ru) | Анти-il-1-бета антитела и способы их применения | |
| PE20212088A1 (es) | Anticuerpos anti-tau y uso de los mismos | |
| JP2020500538A5 (enExample) | ||
| ES2685424T3 (es) | Anticuerpos anti-Jagged1 y procedimientos de uso | |
| PE20220487A1 (es) | Anticuerpos anti-ms4a4a y metodos de uso de los mismos | |
| PE20170935A1 (es) | Anticuerpos anti-her2 e inmunoconjugados | |
| AR106991A1 (es) | Anticuerpos neutralizantes del virus de inmunodeficiencia humana | |
| AR091701A1 (es) | Anticuerpos anti-cd22 e inmunoconjugados | |
| AR086044A1 (es) | Anticuerpos que se unen especificamente a un dominio extracelular de c-kit y usos de los mismos | |
| HRP20200767T1 (hr) | Humanizirana anti-humana cd19 protutijela i postupci uporabe | |
| AR109715A1 (es) | Anticuerpos anti-cd27 | |
| PE20181270A1 (es) | Anticuerpo que neutraliza el virus respiratorio sincitial humano | |
| PE20201186A1 (es) | Anticuerpos antitau y metodos de uso | |
| PE20161245A1 (es) | Anticuerpos especificos del receptor del factor 1 de crecimiento similar a la insulina y usos de los mismos | |
| PE20170953A1 (es) | ANTICUERPOS ANTI-CD79b Y METODOS DE USO | |
| PE20150614A1 (es) | Inmunoconjugados que comprenden un anticuerpo anti-cd79b ligado a un derivado de nemorrubicina | |
| HRP20240719T1 (hr) | Kimerna i humanizirana monoklonska protutijela protiv ljudskog ctla4 i njihova upotreba | |
| PE20161376A1 (es) | Anticuerpos de hemaglutinina contra el virus de la influenza b y metodos de uso | |
| PE20190733A1 (es) | Anticuerpos contra el virus del dengue, polipeptidos que contienen regiones fc variantes, y metodos de uso | |
| AR103713A1 (es) | Anticuerpos contra tau y sus usos | |
| JP2018507220A5 (enExample) | ||
| NZ714482A (en) | Composition and method for diagnosis and treatment of diseases associated with neurite degeneration |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |